Myloral data
Data from a Phase I/II trial by AIMM collaborators show that white blood cells from MS patients respond to oral therapy with bovine myelin by boosting secretion of immune modulators. The immune suppressor, transforming growth factor beta-1 (TGF-beta), was secreted in greater amounts by T cells after oral administration of the agent, which is now in Phase III testing.
As reported in the Journal of Clinical Investigation, 34 patients from the continuation study of the trial were observed for the immune responses of T cell lines isolated from their blood. Treatment consisted of 300 mg bovine myelin daily for at least two years. The preparation, AIMM's Myloral, includes about 7.5 mg of myelin basic protein (MBP) and 15 mg of proteolipid protein (PLP). ...